Cytokinetics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -16.35. In total, the insiders bought 227 583 and sold 319 964 CYTK shares in the last 100 trades.

Insider Power

(Last 100 transactions)
-16.35
Buy 227 583 Shares
Sell 319 964 Shares

Historical Insider Trades

Date Type Action Person Amount
Oct 30, 2024 Common Stock Buy Malik Fady Ibraham 5 300
Oct 30, 2024 Common Stock Sell Malik Fady Ibraham 5 300
Oct 30, 2024 Common Stock Sell Malik Fady Ibraham 2 000
Oct 30, 2024 Non-Qualified Stock Option (Right to Buy) Sell Malik Fady Ibraham 5 300
Oct 28, 2024 Common Stock Buy Wierenga Wendall 4 452
Oct 28, 2024 Common Stock Sell Wierenga Wendall 4 452
Oct 28, 2024 Non-Qualified Stock Option (Right to Buy) Sell Wierenga Wendall 4 452
Oct 15, 2024 Common Stock Buy Malik Fady Ibraham 5 300
Oct 15, 2024 Common Stock Sell Malik Fady Ibraham 5 300
Oct 15, 2024 Common Stock Sell Malik Fady Ibraham 2 000
Oct 15, 2024 Non-Qualified Stock Option (Right to Buy) Sell Malik Fady Ibraham 5 300
Oct 09, 2024 Common Stock Buy Blum Robert I 5 000
Oct 09, 2024 Common Stock Sell Blum Robert I 5 000
Oct 09, 2024 Non-Qualified Stock Option (Right to Buy) Sell Blum Robert I 5 000
Oct 01, 2024 Common Stock Buy Harrington Robert Arthur 237
Oct 01, 2024 Common Stock Buy Henderson John T 403
Oct 01, 2024 Common Stock Buy Kaye Edward M. Md 237
Oct 01, 2024 Common Stock Buy Wierenga Wendall 118
Oct 01, 2024 Common Stock Buy Wysenski Nancy 118
Oct 01, 2024 Common Stock Buy Malik Fady Ibraham 5 300
Oct 01, 2024 Common Stock Sell Malik Fady Ibraham 5 300
Oct 01, 2024 Common Stock Sell Malik Fady Ibraham 2 000
Oct 01, 2024 Non-Qualified Stock Option (Right to Buy) Sell Malik Fady Ibraham 5 300
Sep 30, 2024 Common Stock Buy Blum Robert I 5 000
Sep 30, 2024 Common Stock Sell Blum Robert I 5 000
Click to get the best stock tips daily for free!
ABOUT CYTOKINETICS
Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati...
GOLDEN STAR
Ticker Change Signal Date
NBIX
$116.19
5.18% Oct 29
W
WTW
$292.18
2.44% Oct 29
I
INST
$23.52
0.213% Oct 29
SRCL
$60.88
1.81% Oct 28
EQC
$19.81
0.202% Oct 28

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE